Antibody developed by Dr. Weissman and his colleagues shows promise in a small clinical trial as a safe cancer therapy

An immunotherapy conceived at Stanford appeared safe in an early clinical trial. Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported.